Full Professorship (W3) for Translational Radiation Oncology
DKFZ - German Cancer Research Center
The German Cancer Research Center (DKFZ) in Heidelberg and the Faculty of Medicine at the Heidelberg University jointly invite applications for the following position Full Professorship (W3) for Translational Radiation Oncology in the frame of the German Cancer Consortium (DKTK) commencing as soon as possible. According to the "Jülicher Modell" the successful candidate will be appointed as a full professor of the University of Heidelberg and granted a leave of absence in order to take up employment at the DKFZ. At the DKFZ the professor will head a new division for Translational Radiation Oncology and strengthen clinical research within the Radiation Oncology and Imaging Program of the German Cancer Consortium (DKTK) at the core site, DKFZ-Heidelberg.
The German Cancer Consortium (DKTK) is a joint initiative of the German Federal Ministry of Education and Research (BMBF), the participating states and the DKFZ. The alliance between the DKFZ as the core center, the National Center for Tumor Diseases in Heidelberg and the university partner sites in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, München and Tübingen establishes joint translational cancer research units.The DKTK promotes interdisciplinary research approaches and innovative clinical studies, which will contribute to improved prevention, diagnosis and faster implementation of personalized therapies for cancer patients.
The professorship and the division will be further integrated in the National Center for Radiation Oncology - Heidelberg Institute of Radiation Oncology (NCRO-HIRO) and the National Center for Tumor Diseases (NCT), and is therefore best suited to form a central liaison between the basic - and clinical research activities at the participating institutions. This division will build on the existing translation research pipeline and unique infrastructure provided by HIRO which cover a broad spectrum of research in radiation biology, molecular diagnostics, medical radiation physics, oncotechnology development, functional - and molecular imaging. The infrastructure of HIRO includes the clinical and experimental high-precision particle therapy facility (Heidelberg Ion-Beam Therapy Center, HIT), preclinical and clinical imaging platforms a well as a large spectrum of high-throughput technologies for molecular analysis and radiation biology.
We seek for a highly motivated candidate with an excellent scientific track record to build up a multidisciplinary research team for translation of new developments in radiation biology and physics into clinical applications. The candidate should demonstrate a solid foundation in modern cancer biology, i.e., the fast developing areas of intercellular communication in the interface of the tumor-microenvironment, intratumoral heterogeneity/hierarchies and signaling events governing tumor resistance to multimodal therapies. Moreover, a deep understanding of the biology and potential of therapeutic strategies to ameliorate radiotherapy induced normal tissue complications would be advantageous. Further, excellent expertise in advanced molecular - and functional omics based methods are anticipated. The translational radiation oncology division shall strengthen and further expand the program towards the development of preclinical rationales for multimodal therapies and identification of molecular prognosticators/predictors of radiotherapy response/surrogates, support the establishment of a nation-wide reference clinical trial center for rapid translation of novel multimodal radiotherapy strategies into Phase I/II trials, and in collaboration with DKTK/NCT-facilities, foster the development of a comprehensive tissue bank, fusion of molecular and clinical data, biocomputing and integrative data analysis towards the development of next generation biologically individualized radiation oncology. Overall, we are looking for excellent candidates with innovative strategies to tackle the central translational challenges defined by DKTK in ist radiation oncology program
For clinical research, the candidate will be also employed at the University of Hospital Heidelberg and appointed as a section head of the department of radiation oncology. The professorship is expected to be engaged in the Heidelberg graduate programs, the medical teaching curriculum, the Master programs, and the NCT/DKTK School of Oncology as well as in academic self-administration. The candidate should bring a strong willingness to contribute to existing research networks and establish new collaborations.
Prerequisites for the appointment of professors are a university degree, pedagogic aptitude and an outstanding PhD degree. Scientific achievements going beyond the doctorate, generally proved by a Habilitation (post-doctoral lecturing qualification), a successfully evaluated junior group leadership/professorship or equivalent qualifications are expected (§ 47 of the Baden-Württemberg federal-state law on higher education (Landeshochschulgesetz). Ideally candidates have scientific and administrative leadership experience, as well as a track record in successful acquisition of third-party funds. In case all legal requirements are met, the candidate will receive permanent civil-servant status.